Surface Plasmon Resonance (SPR) Biosensor segmentation by application reveals five dominant domains that collectively drive market growth. Pharmaceutical research accounts for the largest share, roughly 35 % of total revenue, as drug‑discovery programs rely on label‑free kinetic analysis of protein‑ligand interactions. Clinical diagnostics follows with an estimated 25 % contribution, where SPR platforms enable rapid quantification of biomarkers such as cardiac troponin and cytokines in point‑of‑care settings. Academic research represents about 20 % of the market, reflecting extensive use in fundamental studies of biomolecular binding, membrane dynamics, and nanomaterial characterization. Food safety applications, encompassing detection of allergens, pathogens, and contaminants, provide a 12 % slice, supported by regulatory pressure for real‑time screening. Finally, Environmental monitoring contributes roughly 8 %, focusing on trace detection of pollutants and water‑quality parameters. Together, these segments define the market taxonomy and illustrate how each use case underpins the overall size of the SPR biosensor market.